title: Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.
abstract: OBJECTIVE
  To evaluate the effect of tafluprost on the central corneal thickness (CCT) in patients with primary open-angle glaucoma (POAG).
  
  
  METHODS
  This was a prospective study and included 100 eyes of 54 patients with POAG. All patients received tafluprost 0.0015% (Saflutan®) once daily in one or both eyes. CCT was measured by using noncontact pachymetry prior to the treatment and after 6 and 12 months.
  
  
  RESULTS
  Mean CCT of all treated eyes (n = 100) was 547.79 ± 29.48 μm at baseline, 535.61 ± 26.54 μm after 6 months and 533.55 ± 26.45 μm after 12 months (Student's t test, p < 0.0001). Ninety-three percent of all treated eyes showed a decrease of CCT. CCT reduction was more significant within the first six months of the treatment period (Student's t test, p < 0.0001). After 12 months, a CCT reduction >25 μm occurred in 5% of all treated eyes. There was a significant positive correlation between the magnitude of corneal thinning and the initial CCT (Pearson, r = 0.49, p < 0.0001) but not between the magnitude of corneal thinning and intraocular pressure (IOP) reduction (Pearson, r = 0.145, p = 0.15).
  
  
  CONCLUSIONS
  Long-term use of tafluprost may decrease the CCT in patients with POAG. Consequently, clinicians must be aware of prolongated CCT variations that may arise throughout the follow-up period for proper IOP targeting and management.
authors.affiliation: Department of Ophthalmology, University Hospitals of Geneva HUG, Switzerland. Georgios.Panos@hcuge.ch
authors.forename: Georgios D
authors.initials: GD
authors.lastname: Panos
authors.forename: Aristeidis
authors.initials: A
authors.lastname: Konstantinidis
authors.forename: Efstratios
authors.initials: E
authors.lastname: Mendrinos
authors.forename: Vassilios
authors.initials: V
authors.lastname: Kozobolis
authors.forename: Irfan
authors.initials: I
authors.lastname: Perente
authors.forename: Zisis
authors.initials: Z
authors.lastname: Gatzioufas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003315:Cornea / Q000187:drug effects* / Q000473:pathology*; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011460:Prostaglandins F / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D011460:Prostaglandins F; C485333:tafluprost; D015237:Dinoprost